The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition

Inhibition of BET bromodomains (BRDs) has emerged as a promising cancer therapeutic strategy. Accordingly, inhibitors of BRDs such as JQ1 have been actively developed and some have reached clinical testing. However, the mechanisms by which this group of inhibitors exerts their anticancer activity, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Weilong, Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741481/
https://www.ncbi.nlm.nih.gov/pubmed/26415225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741481/
https://www.ncbi.nlm.nih.gov/pubmed/26415225

Ejemplares similares